The estimated Net Worth of Anthony C. Jr. Providenti is at least $699 mil dollars as of 18 May 2021. Mr. Providenti owns over 8,434 units of Covetrus stock worth over $694,937 and over the last 5 years he sold CVET stock worth over $4,329. In addition, he makes $0 as Executive Vice President y Corporate Development at Covetrus.
Anthony has made over 5 trades of the Covetrus stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,434 units of CVET stock worth $177,030 on 18 May 2021.
The largest trade he's ever made was exercising 10,218 units of Covetrus stock on 14 January 2021 worth over $214,476. On average, Anthony trades about 1,532 units every 31 days since 2020. As of 18 May 2021 he still owns at least 33,108 units of Covetrus stock.
You can see the complete history of Mr. Providenti stock trades at the bottom of the page.
Anthony Providenti serves as Executive Vice President, Corporate Development of the Company. Mr. Providenti was having served as our Senior Vice President, Corporate Development since February 2019. Prior to such appointment, Mr. Providenti served in a number of positions at Henry Schein since 2003, including Vice President, Corporate Business Development Group, and Vice President, Strategy and Development, Global Animal Health Group. Mr. Providenti holds a J.D. from Fordham University School of Law and a B.S. in Accounting from Lehigh University.
Anthony Providenti is 53, he's been the Executive Vice President y Corporate Development of Covetrus since 2020. There are 14 older and 12 younger executives at Covetrus. The oldest executive at Covetrus, Inc. is Philip Laskawy, 78, who is the Independent Chairman of the Board.
Anthony's mailing address filed with the SEC is 7, Custom House Street, India Street, Portland, Cumberland County, Maine, 04101, United States.
Over the last 6 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin y Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus executives and other stock owners filed with the SEC include: